When Wegovy was approved in 2021, patients began inquiring about whether Ro could build a product that would give them the “Ro experience” in weight loss: The company went to work at the end of 2021, spent all of 2022 building it, launched in 2023 and is now scaling up, CEO and co-founder Zachariah Reitano explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Reitano sat down with BI analyst Jonathan Palmer to discuss how the Ro platform is uniquely positioned to scale in chronic care, the drivers of unprecedented demand for GLP-1 drugs, how taking friction out of the patient experience led to early success and why he’s trying to recreate his physician father with technology. See omnystudio.com/listener for privacy information.